Questions about research and their answers
Session moderator Kristin Swanson, PhD, asked if the AI could be used with the pathology slide’s visible features to learn more about the underlying biology and pathophysiology of tumors.
“Overlying the HECTOR on to the tissue seems like a logical opportunity to go and then explore the biology and what’s attributed as a high-risk region,” said Dr. Swanson, who is director of the Mathematical NeuroOncology Lab and codirector of the Precision NeuroTherapeutics Innovation Program at Mayo Clinic Arizona, Phoenix.
Ms. Fremond agreed that the AI has the potential to be used that way.”
During the Q&A, an audience member asked how likely the model is to perform in populations that differ significantly from the populations used in her study.
Ms. Fremond responded that the populations used to develop and test the models were in or close to the Netherlands, and little information was available regarding patient ethnicity. “There is a possibility that perhaps we would have a different performance on a population that includes more minorities. That needs to be checked,” said Ms. Fremond.
The study is limited by its retrospective nature.
Ms. Fremond and Dr. Swanson have no relevant financial disclosures.